Guangzhou Lianrui Pharmaceutical

Guangzhou Lianrui Pharmaceutical is a China-based pharmaceutical company and a key subsidiary of the HEC Group (Sunshine Lake Pharma). The company focuses on the research, development, and large-scale manufacturing of high-quality generic and innovative small molecule drugs. Its primary therapeutic areas include anti-infectives, particularly Hepatitis C and influenza, as well as metabolic and psychiatric disorders. Lianrui is known for its involvement in the development and commercialization of the NS5A inhibitor yimitasvir and the NS3/4A protease inhibitor furaprevir. The company operates advanced manufacturing facilities in Guangzhou that comply with international GMP standards.